Status:
COMPLETED
DOAC in Unusual Site Venous Thrombosis
Lead Sponsor:
University of Malta
Collaborating Sponsors:
Università degli Studi dell'Insubria
Conditions:
Splanchnic Vein Thrombosis
Cerebral Vein Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombo...
Eligibility Criteria
Inclusion
- Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries
- Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)
Exclusion
- • Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
358 Patients enrolled
Trial Details
Trial ID
NCT03778502
Start Date
October 1 2019
End Date
December 31 2024
Last Update
July 3 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Health System
Detroit, Michigan, United States, 48202
2
Ottawa Hospital Research Institute
Ottawa, Canada
3
CHU Amiens Picardie
Amiens, France
4
Hôpital de la Cavale Blanche
Brest, France